Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer

• Move reflects increasing investment in AI as driving force for innovation and productivity.
• Company will host Innovation Summit in December focused on AI in R&D.

WASHINGTON, June 5, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role.

Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Science Officer, Danaher, said: “We are delighted to welcome Dr. Stumpe to our team. His extensive experience in leveraging AI to drive scientific and operational progress will be critical in further supporting Danaher’s AI and data strategy to advance innovation.”

Dr. Stumpe most recently served as Chief of AI at Tempus, where he spearheaded AI initiatives aiming to make precision medicine a reality. Prior to Tempus, he founded the Cancer Pathology project at Google – which aimed to enhance the accuracy of cancer detection and grading using AI techniques – and was part of the Kepler team at NASA’s Ames Research Center. Dr. Stumpe holds a Ph.D. in Computational & Theoretical Physics from the Max Planck Institute for Biophysical Chemistry in Germany. He will report to Dr. Gutierrez-Ramos.

Danaher is increasingly focusing on AI through inorganic investment, strengthening internal capabilities, and collaborating with leading academic institutions. In December, the company will host the third annual Danaher Summit, bringing together visionary leaders and innovators to discuss AI’s potential impact on biopharmaceutical research and development.  

ABOUT DANAHER  
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.  

FORWARD-LOOKING STATEMENTS  
Statements in this release that are not strictly historical, including any statements regarding Danaher’s AI and data strategy, AI focus areas and any other events or developments that Danaher believes or anticipates will or may occur in the future are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the factors set forth in Danaher’s SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2024. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, Danaher does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.  

SOURCE Danaher Corporation